Ocular Therapeutix, Inc.
Here’s whether Ocular Therapeutix, Inc. (OCUL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.11% over 10 days); 3-month momentum positive (+34.6%); rising volume confirms the move (1.46x 30d avg). Concerns: RSI 80 — overbought, elevated pullback risk. Currently 32.6% off its 52-week high. Score: +5/7.
OCUL is in a confirmed uptrend, trading above both its 50-day ($9.51) and 200-day ($9.97) moving averages. With an RSI of 79.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -8.7% compares to +20.5% for SPY (trailed the market by 29.1%). The current 32.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.